miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi
The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi
1 other identifier
observational
21
1 country
1
Brief Summary
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of miRNA machinery components such as miRNA maturation and transport factors, microprocessor complex and RISC subunits in cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedFirst Submitted
Initial submission to the registry
September 29, 2011
CompletedFirst Posted
Study publicly available on registry
September 30, 2011
CompletedOctober 16, 2012
October 1, 2012
2.8 years
September 29, 2011
October 15, 2012
Conditions
Study Arms (3)
Cutaneous Melanoma
Cutaneous Melanoma Metastases
Benign Melanocytic Nevi
Eligibility Criteria
Patients with cutaneous melanoma, cutaneous melanoma metastases, benign melanocytic nevi
You may qualify if:
- cutaneous melanoma
- cutaneous melanoma metastases
- benign melanocytic nevi
You may not qualify if:
- other forms of malignancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, North Rhine-Westphalia, 44791, Germany
Related Publications (1)
Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, Bechara FG. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012 Oct;350(1):119-26. doi: 10.1007/s00441-012-1446-0. Epub 2012 Jun 17.
PMID: 22706980RESULT
Biospecimen
human skin
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Falk G Bechara, PD Dr.
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Postdoc
Study Record Dates
First Submitted
September 29, 2011
First Posted
September 30, 2011
Study Start
December 1, 2008
Primary Completion
September 1, 2011
Study Completion
September 1, 2011
Last Updated
October 16, 2012
Record last verified: 2012-10